Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
>
2016
>
Asana BioSciences Announces Acceptance of Its Third IND Application in Oncology
Asana BioSciences Announces Acceptance of Its Third IND Application in Oncology
Read also
FDA Announces New Domestic Generic Drug Fast-Track Review Program
FDA announced a new pilot program designed to provide faster reviews for domestically tested and manufactured generic drugs.
Rocket Company
Rocket ditches blood disorder gene therapy in ongoing pipeline pivot
AAVantgarde Announces FDA
AAVantgarde Announces FDA Orphan Drug Designation and UK CTA approval for AAVB-039 for the Treatment of Stargardt Disease
BriaCell to Present Bria-OTS+™
BriaCell to Present Bria-OTS+™ Preclinical Data at SITC 2025 Annual Meeting
